Drugs / LMW-DS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03613571 | Aug 2018 → Aug 2019 | amyotrophic lateral sclerosis | TikoMed AB | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-09-21 | TikoMed AB | Results TikoMed’s ILB® inhibits cell infection by coronaviruses and modulates reactive cytokine release from microglia in vitro tikomed.com ↗
The study shows that ILB ® blocked ACE2:spike protein interaction and inhibited coronaviral infection. |
| 2022-09-08 | TikoMed AB | Results TikoMed’s drug candidate ILB® inhibited infection of human cells by Dengue, Zika and Yellow Fever viruses in vitro, providing further support for its broad spectrum mechanism of action tikomed.com ↗
In the study, ILB® potently inhibited infection by all the strains of Dengue, Zika and Yellow Fever virus in a concentration-dependent manner with IC50 for ILB® ranging from 31 to 343 μg/ml. |
All press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMW-DS | “This single arm, open label, clinical trial in patients with ALS investigated the safety and tolerability of a novel modified low molecular weight dextran sulphate (LMW-DS,...” PMID 35613082 ↗ May 2022 |
| Known as | ILB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03613571 ↗ |
| Modality | Other / unclassified | “a novel modified low molecular weight dextran sulphate (LMW-DS, named ILB®)” PMID 35613082 ↗ May 2022 |
| Route | Subcutaneous | “ILB will be given as single short-term s.c. injections in the abdomen, the thigh or the buttock” NCT03613571 ↗ |